Chlamydia trachomatis and Neisseria gonorrhoeae by Transcription-Mediated Amplification (TMA), SurePath
2001551
Ordering Recommendation
SurePath media is not preferred when testing for Chlamydia trachomatis and Neisseria gonorrhoeae by transcription-mediated amplification (TMA). Use of transport media other than Aptima specimen collection kit may result in reduced sensitivity. The preferred test is Chlamydia trachomatis and Neisseria gonorrhoeae by Transcription-Mediated Amplification (TMA) (0060241) or if confirmation of positive results by an alternate nucleic acid target is required, refer to Chlamydia trachomatis and Neisseria gonorrhoeae by Transcription-Mediated Amplification (TMA) with Confirmation (2011164).
Mnemonic
CTNG SP
Methodology
Transcription-Mediated Amplification
Performed
Sun-Sat
Reported
1-3 days  
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Specimen Required
Patient Preparation
  
Collect
Cervical brush in SurePath liquid-based Pap test Media. Refer to "Sample Collection for the Diagnosis of STD" under Specimen Handling at www.aruplab.com for specific specimen collection and transport instructions.  
Specimen Preparation
Vortex SurePath media and transfer 1 mL to APTIMA Specimen Transfer Tube (ARUP supply #42711) within 24 hours of collection. Available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787. To reduce the potential for contamination, SurePath specimens should be poured off, using sterile technique,into the APTIMA Specimen Transfer Tube prior to Cytology Testing.  
Storage/Transport Temperature
Refrigerated.  
Unacceptable Conditions
Specimens in any transport media other than indicated above. Specimens from patients that are less than 16 years of age.  
Remarks
Specimen source is required.  
Stability
SurePath Media: Ambient: 24 hours; Refrigerated: 48 hours; Frozen: 1 week
APTIMA Specimen Transfer Tube:
Ambient: 2 weeks; Refrigerated: 1 month; Frozen: 1 month  
Reference Interval
Negative  
Interpretive Data
Use of transport media other than the APTIMA specimen collection kit may result in reduced sensitivity. Specimens should be collected and transported following the instructions in "Sample Collection for the Diagnosis of STD Using Nucleic Acid Amplification Tests" under Specimen Handling at www.aruplab.com.

This test is intended for medical purposes only and is not valid for the evaluation of suspected sexual abuse or for other forensic purposes. In certain contexts, culture may be required to meet applicable laws and regulations for diagnosis of C. trachomatis and N. gonorrhoeae infections. Per 2014 CDC recommendations, this test does not include confirmation of positive results by an alternative nucleic acid target.

See Compliance Statement B: www.aruplab.com/CS
Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
 
Note
 
CPT Code(s)
87491;87591
Components
Component Test Code*Component Chart NameLOINC
2001552C. trachomatis by TMA, SurePath50387-0
2001553N. gonorrhoeae by TMA, SurePath50388-8
2005507Specimen Source31208-2
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • Chlamydia and GC TMA panel
  • CT/GC TMA SurePath
  • Gonorrhea SurePath
  • Nucleic Acid Amplification Test (NAAT)